KR102701695B1 - 항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도 - Google Patents

항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도 Download PDF

Info

Publication number
KR102701695B1
KR102701695B1 KR1020197014600A KR20197014600A KR102701695B1 KR 102701695 B1 KR102701695 B1 KR 102701695B1 KR 1020197014600 A KR1020197014600 A KR 1020197014600A KR 20197014600 A KR20197014600 A KR 20197014600A KR 102701695 B1 KR102701695 B1 KR 102701695B1
Authority
KR
South Korea
Prior art keywords
ser
seq
amino acid
leu
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197014600A
Other languages
English (en)
Korean (ko)
Other versions
KR20190085935A (ko
Inventor
마이클 에이치. 카게이
신시아 에이. 시랄드
Original Assignee
리프 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리프 테라퓨틱스 인코포레이티드 filed Critical 리프 테라퓨틱스 인코포레이티드
Publication of KR20190085935A publication Critical patent/KR20190085935A/ko
Application granted granted Critical
Publication of KR102701695B1 publication Critical patent/KR102701695B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197014600A 2016-10-26 2017-10-26 항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도 Active KR102701695B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662413198P 2016-10-26 2016-10-26
US62/413,198 2016-10-26
PCT/US2017/058555 WO2018081437A1 (en) 2016-10-26 2017-10-26 Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody

Publications (2)

Publication Number Publication Date
KR20190085935A KR20190085935A (ko) 2019-07-19
KR102701695B1 true KR102701695B1 (ko) 2024-08-30

Family

ID=60570180

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197014600A Active KR102701695B1 (ko) 2016-10-26 2017-10-26 항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도

Country Status (14)

Country Link
US (2) US11267876B2 (https=)
EP (1) EP3532099A1 (https=)
JP (2) JP7374765B2 (https=)
KR (1) KR102701695B1 (https=)
CN (1) CN110114087A (https=)
AU (1) AU2017347822B2 (https=)
BR (1) BR112019008279A2 (https=)
CA (1) CA3041325A1 (https=)
IL (1) IL266199B2 (https=)
MA (1) MA46673A (https=)
MX (1) MX2019004940A (https=)
RU (1) RU2019115946A (https=)
SG (1) SG11201903602RA (https=)
WO (1) WO2018081437A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102701695B1 (ko) 2016-10-26 2024-08-30 리프 테라퓨틱스 인코포레이티드 항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도
CA3128526A1 (en) 2019-02-01 2020-08-06 Board Of Regents, The University Of Texas System Monoclonal antibodies against mhc-bound human dickkopf-1 peptides and uses thereof
BR112022004851A2 (pt) * 2019-09-19 2022-08-23 Leap Therapeutics Inc Uso de inibidores de dkk-1 para tratar câncer
EP4061419A1 (en) * 2019-11-22 2022-09-28 Leap Therapeutics, Inc. Methods of treating cancer using dkk-1-inhibitors
EP4471056A4 (en) 2022-01-28 2026-02-18 Shanghai Junshi Biosciences Co Ltd Anti-DKK1 antibodies, pharmaceutical composition and associated uses
US20250222062A1 (en) * 2022-03-24 2025-07-10 The Translational Genomics Research Institute Peptide inhibitors targeting the tbl1-beta-catenin complex
CN116350758B (zh) * 2023-03-16 2024-08-06 郑州大学 肿瘤共享新抗原表位肽或其编码核酸在制备药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7446181B2 (en) * 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
CN101641373B (zh) * 2007-02-08 2015-02-11 默沙东公司 Dkk-1的特异性抗体
WO2009028158A1 (en) 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker
AR075989A1 (es) 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
CN102421798A (zh) 2009-05-07 2012-04-18 诺瓦提斯公司 与dickkopf-1或dickkopf-4或两者的结合分子的组合物及使用方法
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CN103608037B (zh) * 2011-02-01 2016-04-13 香港大学 抗dkk1单克隆抗体用于治疗肝癌的用途
ES2703208T3 (es) * 2013-02-27 2019-03-07 Daiichi Sankyo Co Ltd Método de predicción de la sensibilidad a un compuesto que inhibe la vía de transducción de señales de MAPK
TW201610168A (zh) * 2013-12-02 2016-03-16 安可美德藥物股份有限公司 與Ｗｎｔ途徑抑制劑有關之預測性生物標記之鑑別
KR102701695B1 (ko) 2016-10-26 2024-08-30 리프 테라퓨틱스 인코포레이티드 항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도
BR112022004851A2 (pt) 2019-09-19 2022-08-23 Leap Therapeutics Inc Uso de inibidores de dkk-1 para tratar câncer
EP4061419A1 (en) 2019-11-22 2022-09-28 Leap Therapeutics, Inc. Methods of treating cancer using dkk-1-inhibitors
WO2023039249A1 (en) 2021-09-10 2023-03-16 Leap Therapeutics, Inc. Combination therapy
KR20250057775A (ko) 2022-07-12 2025-04-29 리프 테라퓨틱스 인코포레이티드 조합 요법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J Clin Oncol, 34(4) Abstract No.111(온라인 게재일 2016.02.01.)*

Also Published As

Publication number Publication date
WO2018081437A1 (en) 2018-05-03
CA3041325A1 (en) 2018-05-03
JP7374765B2 (ja) 2023-11-07
KR20190085935A (ko) 2019-07-19
SG11201903602RA (en) 2019-05-30
RU2019115946A (ru) 2020-11-27
EP3532099A1 (en) 2019-09-04
US12319730B2 (en) 2025-06-03
IL266199B1 (en) 2024-10-01
AU2017347822A1 (en) 2019-05-09
AU2017347822B2 (en) 2025-01-16
RU2019115946A3 (https=) 2021-01-26
US20220289831A1 (en) 2022-09-15
JP2023133432A (ja) 2023-09-22
IL266199B2 (en) 2025-02-01
CN110114087A (zh) 2019-08-09
MX2019004940A (es) 2019-09-26
US20190284264A1 (en) 2019-09-19
BR112019008279A2 (pt) 2019-07-09
IL266199A (en) 2019-06-30
JP2019533693A (ja) 2019-11-21
US11267876B2 (en) 2022-03-08
MA46673A (fr) 2019-09-04

Similar Documents

Publication Publication Date Title
KR102701695B1 (ko) 항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도
US20240390489A1 (en) Methods of increasing strength and functionality with gdf8 inhibitors
TWI832808B (zh) 中和抗tl1a之單株抗體
US11884734B2 (en) Anti-MET antibodies and methods of use thereof
KR102596852B1 (ko) 항-프로/잠재성-미오스타틴 항체 및 그의 용도
JP5903382B2 (ja) 治療用ｄｌｌ４結合タンパク質
JP2011526244A (ja) 炎症の処置方法
TW201029665A (en) Neutralizing antibodies against GDF-8 and uses therefor
KR20170137073A (ko) 항-인간 ｎｏｔｃｈ4 항체
CN105431455A (zh) 抗激活素a化合物对受试者的施用
KR20220131223A (ko) Dkk-1 억제제를 사용하여 암을 치료하는 방법
JP7747350B2 (ja) Ｓｆｒｐ２アンタゴニストを含む組成物及び方法
CN108472359B (zh) Trail受体结合剂及其用途
JP2013505285A (ja) 癌治療のためのＤｓｇ２アンタゴニスト
CN115279393A (zh) 以介白素24或介白素20拮抗剂治疗组织纤维化和/或损伤和/或器官衰竭
HK40035170A (en) Methods and compositions for treatment of amyloid deposition diseases

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190521

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201019

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221021

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230831

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240530

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240828

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240828

End annual number: 3

Start annual number: 1

PG1601 Publication of registration